Latest data on Zafgen's diabetes pill does little to soothe investors

The mid-stage trial data touted by Boston biotech Zafgen Inc. regarding its lead drug to treat type 2 diabetes appeared to show the drug works with no serious side effects. But the announcement seemed to do little to assuage investors in light of the fact that the drug remains on hold due to cardiovascular concerns. Zafgen (Nasdaq: ZFGN) announced that its lead program, ZGN-1061, met its primary endpoints in an early readout of the Phase 2 clinical trial data. The biotech believes the drug can…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news